The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer.
Lei Zheng; Kelly Foley; Lanqing Huang; Ashley Leubner; Guanglan Mo; Kelly Olino; Barish H Edil; Masamichi Mizuma; Rajni Sharma; Dung T Le; et al. (Profiled Authors: Peter Illei; Jennifer Van Eyk; Daniel Laheru; Dung Le; Lei Zheng; Elizabeth Jaffee; Lanqing Huang; Robert Anders; Anirban Maitra; Barish Edil)
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. email@example.com
PloS one 2011;6(4):e19390.
The aggressiveness of pancreatic ductal adenocarcinoma (PDA) is characterized by its high metastatic potential and lack of effective therapies, which is the result of a lack of understanding of the mechanisms involved in promoting PDA metastases. We identified Annexin A2 (ANXA2), a member of the Annexin family of calcium-dependent phospholipid binding proteins, as a new molecule that promotes PDA invasion and metastases. We found ANXA2 to be a PDA-associated antigen recognized by post-treatment sera of patients who demonstrated prolonged survival following treatment with a PDA-specific vaccine. Cell surface ANXA2 increases with PDA development and progression. Knockdown of ANXA2 expression by RNA interference or blocking with anti-ANXA2 antibodies inhibits in vitro invasion of PDA cells. In addition, post-vaccination patient sera inhibits in vitro invasion of PDA cells, suggesting that therapeutic anti-ANXA2 antibodies are induced by the vaccine. Furthermore, cell-surface localization of ANXA2 is tyrosine 23 phosphorylation-dependent; and tyrosine 23 phosphorylation is required for PDA invasion. We demonstrated that tyrosine 23 phosphorylation resulting in surface expression of ANXA2 is required for TGFβ-induced, Rho-mediated epithelial-mesenchymal transition (EMT), linking the cellular function of ANXA2 which was previously shown to be associated with small GTPase-regulated cytoskeletal rearrangements, to the EMT process in PDA. Finally, using mouse PDA models, we showed that shRNA knock-down of ANXA2, a mutation at tyrosine 23, or anti-ANXA2 antibodies, inhibit PDA metastases and prolong mouse survival. Thus, ANXA2 is part of a novel molecular pathway underlying PDA metastases and a new target for development of PDA therapeutics.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Eric Lutz; Charles J Yeo; Keith D Lillemoe; Barbara Biedrzycki; Barry Kobrin; Joseph Herman; Elizabeth Sugar; Steven Piantadosi; John L Cameron; Sara Solt; et al.Annals of surgery 2011;253(2):328-35.
Ihid C Leao; Priya Ganesan; Todd D Armstrong; Elizabeth M JaffeeClinical and translational science 2008;1(3):228-39.
Xin-Jian Li; Choon Kiat Ong; Yun Cao; Yan-Qun Xiang; Jian-Yong Shao; Aikseng Ooi; Li-Xia Peng; Wen-Hua Lu; Zhongfa Zhang; David Petillo; et al.Cancer research 2011;71(8):3162-72.
Appears in this Publication
Author of this Publication